PTEN and acute lymphoblastic leukemia: For example, around 50% of T-cell acute lymphoblastic leukemia (T-ALL) patients have mutations in the NOTCH1 receptor leading to inhibition of PTEN which thereby activates AKT and promotes resistance to glucocorticoid therapy, an important indicator of therapeutic failure in T-ALL [5, 6].